Mondi, Annalisa
 Distribuzione geografica
Continente #
EU - Europa 1.468
NA - Nord America 1.093
AS - Asia 421
SA - Sud America 62
AF - Africa 9
Totale 3.053
Nazione #
US - Stati Uniti d'America 1.067
DE - Germania 397
PL - Polonia 311
FR - Francia 224
SE - Svezia 167
SG - Singapore 163
CN - Cina 147
IT - Italia 124
UA - Ucraina 88
BR - Brasile 53
GB - Regno Unito 51
IN - India 42
IE - Irlanda 40
FI - Finlandia 27
ID - Indonesia 23
CA - Canada 19
TR - Turchia 17
RU - Federazione Russa 11
BE - Belgio 8
CM - Camerun 8
IR - Iran 7
HK - Hong Kong 6
AT - Austria 4
VN - Vietnam 4
AR - Argentina 3
ES - Italia 3
KR - Corea 3
BD - Bangladesh 2
CH - Svizzera 2
DK - Danimarca 2
EC - Ecuador 2
JM - Giamaica 2
LT - Lituania 2
NL - Olanda 2
PA - Panama 2
PH - Filippine 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
CL - Cile 1
DO - Repubblica Dominicana 1
HN - Honduras 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MM - Myanmar 1
MN - Mongolia 1
MX - Messico 1
NG - Nigeria 1
PE - Perù 1
PT - Portogallo 1
PY - Paraguay 1
RS - Serbia 1
VE - Venezuela 1
Totale 3.053
Città #
Kraków 310
Chandler 214
Jacksonville 82
Singapore 75
Ashburn 73
New York 51
Dublin 40
San Mateo 40
Ann Arbor 39
Nanjing 35
Milan 34
Redmond 33
Dearborn 30
Houston 29
Nürnberg 27
Cattolica 26
Jakarta 23
Wilmington 23
Lawrence 22
Redwood City 20
Lancaster 19
Boston 18
Woodbridge 17
Izmir 16
Nanchang 16
Los Angeles 15
Ottawa 13
The Dalles 12
Changsha 9
Brussels 8
Frankfurt am Main 8
Hebei 8
Leawood 8
Rome 8
Boardman 7
Chicago 7
Fairfield 7
Falls Church 7
Lauterbourg 7
Mountain View 7
Seattle 7
Shenyang 7
Beijing 6
Fremont 6
London 6
Norwalk 6
Augusta 5
Guangzhou 5
Hong Kong 5
Jinan 5
Kunming 5
Moscow 5
Munich 5
Paris 5
Tianjin 5
Bari 4
Hefei 4
Simi Valley 4
University Park 4
Washington 4
Auburn Hills 3
Bexley 3
Busto Arsizio 3
Cambridge 3
Clearwater 3
Helsinki 3
Kish 3
Marseille 3
Modena 3
Pune 3
Roubaix 3
Shanghai 3
São Paulo 3
Toronto 3
Aparecida de Goiânia 2
Bologna 2
Bremen 2
Campinas 2
Cravinhos 2
Düsseldorf 2
Faenza 2
Fuzhou 2
Guarulhos 2
Hangzhou 2
Hanoi 2
Henderson 2
Nanning 2
Osasco 2
Portsmouth 2
San Jose 2
Vancouver 2
Vienna 2
Zurich 2
Acrelândia 1
Almaty 1
Amsterdam 1
Andover 1
Ardabil 1
Bangalore 1
Bishkek 1
Totale 1.633
Nome #
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 235
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 190
Liver fibrosis is associated with cognitive impairment in HIV-positive patients 179
Prevalence of osteoporosis and predictors of low BMD in a cohort of HIV-1-infected patients in Rome: features of a population at high risk 176
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 171
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 167
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 162
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 145
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 145
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 144
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 134
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 131
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 123
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 116
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 111
Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. 107
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 107
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 103
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 99
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 96
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons 94
Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients 80
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 79
Totale 3.094
Categoria #
all - tutte 10.405
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.405


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202020 0 0 0 0 0 0 0 0 0 0 0 20
2020/2021190 10 24 4 17 27 15 12 5 35 4 32 5
2021/2022258 22 17 9 28 12 18 4 38 12 26 30 42
2022/2023491 75 87 32 74 44 57 7 43 62 0 5 5
2023/2024264 12 77 6 26 15 66 11 0 4 4 30 13
2024/2025405 7 16 26 24 74 15 2 31 96 33 80 1
Totale 3.094